Skip to main content
Caplight Logo









PanTera

PanTera

Private
MolHealthcare & Life Scienceshttps://pantera-life.com/

Last Round

Series A

Sep 11, 2024

Est. Valuation

$308.3M

Total Funding Raised

$110.3M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PanTera is a life sciences company that produces actinium-225, a radioisotope used in next-generation radiopharmaceuticals for targeted cancer therapy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

actinium-225 productionAc-225 supplytargeted alpha therapyTATradiopharmaradioisotope manufacturingmedical isotope supplyalpha-emitting radioisotopeactive pharmaceutical ingredientAPIradiopharmaceutical therapyphotonuclear productionpharma supply chainclinical trial supply

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PanTera Comparables

Compare PanTera with similar companies based on industry and business-model similarity.

PanTera comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AlfaRim Medical
85%
Niowave Inc.
79%
Nusano
78%

PanTera Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 11, 2024
DebtSep 11, 2024
Convertible DebtSep 22, 2022

Key People

Founding team and executive leadership

Samy Bertrand

CTO

Executive Team

PanTera Investors

Notable investors and investment history

PanTera investors
InvestorRounds
Federal Holding and Investment CompanyConvertible Debt, Series A
EQT Life SciencesSeries A
KorysSeries A
Paladin Capital GroupSeries A
KBC Group N.V.Debt
PMVSeries A
EurazeoSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Grew 15% QoQ, from 59 to 68 employees.

  • Dec 22, 2025

    Grew 19% QoQ, from 42 to 50 employees.

PanTera Filings

Explore SEC and related filing metadata, where available.

PanTera filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PanTera's valuation, stock price, and market status.

Is PanTera a public or private company?

PanTera is a private company.

What is the current stock price of PanTera?

PanTera is a private company with no public stock price. No recent secondary market data is available.

How much is PanTera worth (valuation)?

PanTera's valuation is estimated at $308.3M based on funding round data.

Can I buy PanTera stock?

PanTera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PanTera's last funding round?

PanTera's most recent funding round was Series A on September 11, 2024.

Who are the main investors in PanTera?

Key investors in PanTera include EQT Life Sciences.

Will PanTera IPO soon?

No public IPO plans have been announced for PanTera.

How can I track PanTera secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PanTera's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMol
Employee Range44
Year Founded2022
Last FundingSep 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?